EUVIMEDEUVIMED entdecken
Crossref

Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688

Christina Battista iD, Lisl K M Shoda, Paul B Watkins, Esther Groettrup-Wolfers, Antje Rottmann, Marian Raschke, Grant T Generaux

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.3010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Christina Battista und 6 weiteren Autor:innen. Beteiligte Einrichtung: DILIsym Services division, Simulations Plus, Inc., Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions, Alanine, Phenanthrenes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BAY1128688 is a selective inhibitor of AKR1C3, investigated recently in a trial that was prematurely terminated due to drug‐induced liver injury. These unexpected observations prompted use of the quantitative systems toxicology model, DILIsym, to determine possible mechanisms of hepatotoxicity. Using mechanistic in vitro toxicity data as well as clinical exposure data, DILIsym predicted the potential for BAY1128688 to cause liver toxicity (elevations in serum alanine aminotransferase (ALT)) and elevations in serum bilirubin. Initial simulations overpredicted hepatotoxicity and bilirubin elevations, so the BAY1128688 representation within DILIsym underwent optimization. The liver partition coefficient K p was altered to align simulated bilirubin elevations with those observed clinically. Altering the mode of bile acid canalicular and basolateral efflux inhibition was necessary to accurately predict ALT elevations. Optimization results support that bilirubin elevations observed early during treatment are due to altered bilirubin metabolism and transporter inhibition, which is independent of liver injury. The modeling further supports that on‐treatment ALT elevations result from inhibition of bile acid transporters, particularly the bile salt excretory pump, leading to accumulation of toxic bile acids. The predicted dose‐dependent intrinsic hepatotoxicity may increase patient susceptibility to an adaptive immune response, accounting for ALT elevations observed after completion of treatment. These BAY1128688 simulations provide insight into the mechanisms behind hepatotoxicity and bilirubin elevations and may inform the potential risk posed by future compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryDrug-Related Side Effects and Adverse ReactionsAlaninePhenanthrenesPropionatesHumansAldo-Keto Reductase Family 1 Member C3Bile Acids and SaltsBilirubinLiverNitrilesSulfones

Substanzen

Aldo-Keto Reductase Family 1 Member C3Bile Acids and SaltsBilirubinAlaninePhenanthrenesPropionates3-(4-methylphenylsulfonyl)-2-propenenitrileNitrilesSulfonesAKR1C3 protein, human

Autor:innen und Institutionen

  • DILIsym Services division, Simulations Plus, Inc., Durham, North Carolina, USA.
  • Eshelman School of Pharmacy, Institute for Drug Safety Sciences, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Pharmaceuticals Division, Pharmacovigilance, Bayer AG, Berlin, Germany.
  • Pharmaceuticals Division, Research & Early Development, Bayer AG, Berlin, Germany.
  • Bristol Myers Squibb, Princeton, New Jersey, USA.

ORCID-Profile: Christina Battista

Zitieren

APA

Battista, C., Shoda, L. K. M., Watkins, P. B., Groettrup-Wolfers, E., Rottmann, A., Raschke, M., & Generaux, G. T. (2023). Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3010

Vancouver

Battista C, Shoda LKM, Watkins PB, Groettrup-Wolfers E, Rottmann A, Raschke M, et al. Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.3010

BibTeX
@article{Battista2023,
  author = {Battista, Christina and Shoda, Lisl K M and Watkins, Paul B and Groettrup-Wolfers, Esther and Rottmann, Antje and Raschke, Marian and Generaux, Grant T},
  title = {Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.3010}
}
Kostenlos starten →